Expression of Feline Interferon-.ALPHA. Subtypes in Esherichia coli, and Their Antiviral Activity and Animal Species Specificity

Taira, Osamu; Suzuki, Makoto; Takeuchi, Yûkô; Aramaki, Yoshitaka; Sakurai, Itsuki; Watanabe, Takao; Motokawa, Kenji; Arai, Setsuo; Sato, Hisaaki; Maehara, Nobutoshi

doi:10.1292/jvms.67.543

Cited by 9 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Feline interferon-omega (licensed for the treatment of canine parvovirus and feline leukaemia virus (FeLV] infections in some European countries) inhibits FCV replication in vitro; controlled field studies, however, are not available [EBM grade IV]. 39,40 In addition, no vaccine protects against all FCV field strains.…”

Section: Antiviral Therapymentioning

confidence: 99%

Feline Calicivirus Infection: ABCD Guidelines on Prevention and Management

Radford¹,

Addie²,

Belák³

et al. 2009

Journal of Feline Medicine and Surgery

142

156

View full text Add to dashboard Cite

Two injections, at 9 and 12 weeks of age, are recommended, followed by a first booster 1 year later. In high-risk situations, a third vaccination at 16 weeks is recommended. Boosters should be given every 3 years. However, cats in high-risk situations should be revaccinated annually. Cats that have recovered from caliciviral disease are probably not protected for life, particularly if infected with different strains. Vaccination of these cats is still recommended.

show abstract

Section: Antiviral Therapymentioning

confidence: 99%

Feline Calicivirus Infection: ABCD Guidelines on Prevention and Management

Radford¹,

Addie²,

Belák³

et al. 2009

Journal of Feline Medicine and Surgery

142

156

View full text Add to dashboard Cite

show abstract

“…Although some broad-spectrum antivirals are effective against FCV in cell culture, they are too toxic for use in the cat [83]. Interferon is used by some, although to the authors' knowledge, published evidence for its effectiveness remains limited to in vitro studies [106], and it is not licensed for control of FCV-disease in Europe. Experimental trials of chimeric mouse-cat monoclonal antibodies have shown some promise in treatment [111,112].…”

Section: Treatmentmentioning

confidence: 99%

Feline calicivirus

et al. 2007

View full text Add to dashboard Cite

-Feline calicivirus (FCV) is an important and highly prevalent pathogen of cats. It belongs to the family Caliciviridae which includes other significant pathogens of man and animals. As an RNA virus, high polymerase error rates convey upon FCV a high genome plasticity, and allow the virus to respond rapidly to environmental selection pressures. This makes the virus very adaptable and has important implications for clinical disease and its control. Being genetically diverse, FCV is associated with a range of clinical syndromes from inapparent infections to relatively mild oral and upper respiratory tract disease with or without acute lameness. More recently, highly virulent forms of the virus have emerged associated with a systemic infection that is frequently fatal. A proportion of FCV infected cats that recover from acute disease, remain persistently infected. In such cats, virus evolution is believed to help the virus to evade the host immune response. Such longterm carriers may only represent a minority of the feline population but are likely to be crucial to the epidemiology of the virus. Vaccination against FCV has been available for many years and has effectively reduced the incidence of clinical disease. However, the vaccines do not prevent infection and vaccinated cats can still become persistently infected. In addition, FCV strain variability means that not all strains are protected against equally. Much progress has been made in understanding the biology and pathogenesis of this important feline virus. Challenges for the future will necessarily focus on how to control the variability of this virus particularly in relation to emerging virulent strains and vaccination.

show abstract

“…There are currently no direct acting antiviral drugs registered for the treatment of FCV, although the immune modulating drug recombinant feline interferon-v (rFeIFNv), which likely has indirect antiviral properties, has a registered indication for FCV treatment. Efficacy of both human and feline interferons has been demonstrated in vitro against FCV (Fulton and Burge, 1985;Mochizuki et al, 1994;Taira et al, 2005;Truyen et al, 2002) and the use of rFeIFN-v has been reported to have a positive therapeutic effect in FCV infected cats in experimental and field efficacy trials (Ninomiya et al, 1991;Ohe et al, 2008). Treatment with rFeIFN-v was also associated with an improvement in clinical signs in cats with refractory FCGS in a double-blinded placebo-controlled study, however FCV shedding was not monitored, making it unclear whether the improvement was due to the antiviral or immunomodulatory properties of interferon (Hennet et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Antiviral effect of mefloquine on feline calicivirus in vitro

McDonagh

Sheehy

Fawcett

et al. 2015

Veterinary Microbiology

View full text Add to dashboard Cite

Feline calicivirus (FCV) is an important viral pathogen of domestic cats causing clinical signs ranging from mild to severe oral ulceration or upper respiratory tract disease through to a severe fatal systemic disease. Current therapeutic options are limited, with no direct acting antivirals available for treatment. This study screened a panel of 19 compounds for potential antiviral activity against FCV strain F9 and recent field isolates in vitro. Using a resazurin-based cytopathic effect (CPE) inhibition assay, mefloquine demonstrated a marked inhibitory effect on FCV induced CPE, albeit with a relatively low selectivity index. Orthogonal assays confirmed inhibition of CPE was associated with a significant reduction in viral replication. Mefloquine exhibited a strong inhibitory effect against a panel of seven recent FCV isolates from Australia, with calculated IC50 values for the field isolates approximately 50% lower than against the reference strain FCV F9. In vitro combination therapy with recombinant feline interferon-ω, a biological response modifier currently registered for the treatment of FCV, demonstrated additive effects with a concurrent reduction in the IC50 of mefloquine. These results are the first report of antiviral effects of mefloquine against a calicivirus and support further in vitro and in vivo evaluation of this compound as an antiviral therapeutic for FCV.

show abstract

Expression of Feline Interferon-.ALPHA. Subtypes in Esherichia coli, and Their Antiviral Activity and Animal Species Specificity

Cited by 9 publications

References 21 publications

Feline Calicivirus Infection: ABCD Guidelines on Prevention and Management

Feline Calicivirus Infection: ABCD Guidelines on Prevention and Management

Feline calicivirus

Antiviral effect of mefloquine on feline calicivirus in vitro

Contact Info

Product

Resources

About